Final Results

AI SummaryClose X

GENinCode Plc reported a 14% increase in revenue to £3.1 million for the year ended December 31, 2025, driven by growth in the US and Europe, with gross profit improving to £1.8 million and margins reaching 59%. Despite this, the adjusted EBITDA loss widened to £4.9 million due to increased commercial support and reduced R&D tax credits, while cash reserves stood at £0.8 million. The company is progressing with its FDA submission for CARDIO inCode-Score, aiming for Q3 2026, and has a collaboration with Thermo Fisher for manufacturing and distribution. Post-period, GENinCode successfully raised £4.7 million to support its commercial scale-up.

Disclaimer*

Companies

GENinCode (GENI)
UK 100

Latest directors dealings